Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Launched by HOSPITAL DE CLINICAS DE PORTO ALEGRE · Oct 31, 2016

Keywords

ClinConnect Summary

This clinical trial is studying how well a medication called methylphenidate (MPH) works for adults with Attention Deficit/Hyperactivity Disorder (ADHD). MPH is commonly used to help manage ADHD symptoms, but different people may need different doses, and their responses to the medication can vary. Researchers want to understand what factors—like genetics—might affect how well individuals respond to MPH treatment.

To participate in this study, you need to be of White Brazilian European descent and have been diagnosed with ADHD according to specific guidelines. You should also be eligible to start treatment with immediate-release MPH. However, if you are currently taking stimulant medication, have certain neurological conditions, or have had serious mental health issues like psychosis, you would not be eligible. If you join the trial, you can expect to receive the medication and participate in assessments to help the researchers gather information on how well it works for you and others in the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • White Brazilian of European descent
• • Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
• • Eligibility to immediate-release MPH (IR-MPH) treatment
• Exclusion Criteria:
• • Contraindication for IR-MPH use
• • Current stimulant treatment
• • Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
• • Current or past history of psychosis
• • Estimated intelligence quotient score lower than 70